Shanghai Junshi Biosciences Co., Ltd. (688180.SS) SHH
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Shanghai Junshi Biosciences Co., Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
2578
First IPO Date
July 15, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Cong Li | Co-CEO & Executive Director | 1.78M | 1964 |
| Jianjun Zou | GM, Chief Executive Officer & Executive Director | 9.9M | 1971 |
| Xin Li | Senior Vice President of Government Affairs & Executive Director | 2.37M | 1979 |
| Sheng Yao | Deputy GM, Senior Vice President & Executive Director | 2.94M | 1975 |
| Zhuobing Zhang | Deputy GM & Executive Director | 3.53M | 1967 |
| Ning Li | Executive Vice-Chairman of the Board | 3.6M | 1961 |
| Jun Xiong | Executive Chairman | 3.91M | 1974 |
| Gang Wang | Chief Quality Officer, Senior VP of Industry Affairs & Executive Director | 4.98M | 1957 |
| Zhengyu Wang | Joint Company Secretary | 0 | 1995 |
| Baohong Xu | Chief Financial Officer | 0 | 1979 |
Description
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
